- Home
- HTD vs GYRE Comparison
HTD vs GYRE Comparison
Compare HTD & GYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HTD
- GYRE
- Stock Information
- Founded
- HTD 2004
- GYRE 2002
- Country
- HTD United States
- GYRE United States
- Employees
- HTD N/A
- GYRE N/A
- Industry
- HTD Finance Companies
- GYRE Biotechnology: Pharmaceutical Preparations
- Sector
- HTD Finance
- GYRE Health Care
- Exchange
- HTD Nasdaq
- GYRE Nasdaq
- Market Cap
- HTD 863.8M
- GYRE 755.7M
- IPO Year
- HTD N/A
- GYRE N/A
- Fundamental
- Price
- HTD $24.60
- GYRE $7.54
- Analyst Decision
- HTD
- GYRE Strong Buy
- Analyst Count
- HTD 0
- GYRE 2
- Target Price
- HTD N/A
- GYRE $17.00
- AVG Volume (30 Days)
- HTD 92.3K
- GYRE 88.4K
- Earning Date
- HTD 01-01-0001
- GYRE 11-13-2025
- Dividend Yield
- HTD 8.59%
- GYRE N/A
- EPS Growth
- HTD N/A
- GYRE N/A
- EPS
- HTD N/A
- GYRE 0.02
- Revenue
- HTD N/A
- GYRE $102,189,000.00
- Revenue This Year
- HTD N/A
- GYRE $15.25
- Revenue Next Year
- HTD N/A
- GYRE $33.14
- P/E Ratio
- HTD N/A
- GYRE $444.13
- Revenue Growth
- HTD N/A
- GYRE N/A
- 52 Week Low
- HTD $16.17
- GYRE $6.11
- 52 Week High
- HTD $22.13
- GYRE $19.00
- Technical
- Relative Strength Index (RSI)
- HTD 47.16
- GYRE 44.16
- Support Level
- HTD $24.46
- GYRE $7.75
- Resistance Level
- HTD $25.20
- GYRE $8.37
- Average True Range (ATR)
- HTD 0.31
- GYRE 0.46
- MACD
- HTD -0.04
- GYRE -0.06
- Stochastic Oscillator
- HTD 32.58
- GYRE 3.09
About HTD John Hancock Tax Advantaged Dividend Income Fund of Beneficial Interest
John Hancock Tax-advantaged Div Inc Fd is a closed-end, diversified management investment company. Its investment objective is to provide a high after-tax total return from dividend income and capital appreciation. The fund's portfolio composition consists of common stocks, preferred securities, corporate bonds, convertible bonds, and short-term investments. Its sector composition comprises utilities, financials, energy, telecommunication services, industrials, healthcare, real estate, consumer discretionary and short-term investments.
About GYRE Gyre Therapeutics Inc.
Gyre Therapeutics Inc is a commercial-stage pharmaceutical company developing and commercializing small-molecule anti-inflammatory and anti-fibrotic drugs targeting organ diseases, focusing specifically on organ fibrosis. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.